DFBTA is a highly effective and orally active inhibitor of ANO1, specifically the calcium-activated chloride channel anoctamin-1. It exhibits potent inhibitory activity, with an IC 50 of 24 nM. Notably, DFBTA demonstrates significant analgesic efficacy in treating inflammatory pain [1].

DFBTA shows very weak cytotoxicity and cardiotoxicity (HEK293 proliferation IC50 > 30 μM, hERG IC50 > 30 μM) [1]

DFBTA (C57BL/6 mice; 40-80 mg/kg, IG; 40 mg/kg, IV; once) shows weak acute toxicity, with mouse minimum lethal dosage (MLD) > 1000 mg/kg [1]. DFBTA (C57BL/6 mice, 1000 mg/kg, Orally, once) shows excellent pharmacokinetics properties with oral bioavailability > 75% and little brain penetration (<1.5% brain/plasma) [1].